RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
about
Shedding new light on neurodegenerative diseases through the mammalian target of rapamycinSulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways.mTOR-dependent signalling in Alzheimer's diseaseC/EBPβ regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusionRTP801/REDD1: a stress coping regulator that turns into a troublemaker in neurodegenerative disordersPRAS40 plays a pivotal role in protecting against stroke by linking the Akt and mTOR pathwaysRTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activationRTP801/REDD1 regulates the timing of cortical neurogenesis and neuron migrationTranscriptome sequencing and annotation for the Jamaican fruit bat (Artibeus jamaicensis)Removal of FKBP12 enhances mTOR-Raptor interactions, LTP, memory, and perseverative/repetitive behaviorActivation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's diseaseRotenone induction of hydrogen peroxide inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E pathways, leading to neuronal apoptosis.Intracellular signalling pathways in dopamine cell death and axonal degeneration.Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.Fatty acid synthase inhibition engages a novel caspase-2 regulatory mechanism to induce ovarian cancer cell death.Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR.Oxidant stress and signal transduction in the nervous system with the PI 3-K, Akt, and mTOR cascademTOR: on target for novel therapeutic strategies in the nervous system.Prostaglandin receptor EP2 protects dopaminergic neurons against 6-OHDA-mediated low oxidative stress.Autism spectrum disorder causes, mechanisms, and treatments: focus on neuronal synapses.Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.Calcium/calmodulin-dependent protein kinase II links ER stress with Fas and mitochondrial apoptosis pathways.Cell death pathways in Parkinson's disease: proximal triggers, distal effectors, and final steps.Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.Mitophagy and Parkinson's disease: the PINK1-parkin link.Loss of NEDD4 contributes to RTP801 elevation and neuron toxicity: implications for Parkinson's disease.TOR on the brain.The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis.mTOR in Brain Physiology and Pathologies.Diterpenes: Advances in Neurobiological Drug Research.mTOR Signaling in Parkinson's Disease.Sestrin2 Protects Dopaminergic Cells against Rotenone Toxicity through AMPK-Dependent Autophagy Activation.Molecular changes in the postmortem parkinsonian brain.Neurotoxin-induced DNA damage is persistent in SH-SY5Y cells and LC neurons.Dysregulated mTORC1-Dependent Translational Control: From Brain Disorders to Psychoactive Drugs.Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease.Implication of REDD1 in the activation of inflammatory pathways.Use of PC12 cells and rat superior cervical ganglion sympathetic neurons as models for neuroprotective assays relevant to Parkinson's disease.
P2860
Q27015640-F47B3CD0-EC93-4C51-92E8-F9F0C78B9C07Q27314642-BA596781-D51C-4931-A8B7-ECFE39817FA8Q28308319-AB4912C5-97C3-4918-814A-1E8F4E6FD905Q28391156-4F6D1288-6C5F-44AE-8DCC-40C4636E3312Q28395230-568D6DC4-611A-4382-895B-2BB77D3AEB5EQ28565929-5F308688-A0A8-4D06-BD94-2F7B1FAB3C3CQ28568796-A6D6D2C3-08C1-400A-B711-63CA7DBE4FDFQ28574744-9B4D66CB-DB31-4A70-B623-367444F87699Q28712013-9E190EA5-51D8-4035-B2A3-85F4C10016CDQ30485596-B5BD753B-FFAB-491B-A1A5-40468F67908DQ33690517-51921162-EF54-4AF2-8AF7-A11225DCC4D3Q34760248-D894B9C1-A167-47C2-B91E-797C2FF83D2FQ34936423-BE1EB296-BE7C-46FB-BDB2-D66CAF682CDFQ35028378-6A6D1003-8883-47C7-A7FD-4418D172415AQ35122562-B6647141-E26C-4B94-A47D-E48A9D4B74A6Q35157985-3E30882A-05C3-4929-8280-7B542A665559Q35679526-39D56CB3-562A-4240-A214-37C28CCBDC8BQ36379761-7BDB2FA8-B148-46ED-AA74-757B61C62FBCQ36432388-53641D59-899F-4846-B03D-21193C597334Q36501214-F36B536B-850B-4381-9A41-8F537FCFD743Q36943164-F951A1D7-159E-4E56-AB1F-439FB8393E5CQ37068738-035D21C3-27C5-4BE5-9853-AFCD8B646F85Q37076753-BA3410A3-09B7-4127-B4B2-94022319A15EQ37363053-F25BE666-52E1-4334-8978-A9EED3E69A4EQ37376117-4737157B-99F8-4D05-87B1-E4F6048B09BCQ37578490-1B158AD1-8E5A-4391-A4EE-52EECE36CF08Q37587126-6E635654-8E2E-4A28-840E-752E92070E33Q37644778-56F47360-6E92-4B8A-B328-C6D24BB90C9EQ37789848-D5C1C5DF-9563-4841-A195-BF7832647005Q38028872-47FD86D2-4F44-4D88-B32B-9674F1BF1774Q38565769-F7FB2CAA-270F-40B1-8D15-9949B3FDA9A0Q38791506-4D34E4E6-CF05-4A36-90C9-FDE888327E31Q38855225-CE4C52ED-5CB6-4F7D-9D00-A23B810E8B17Q38868889-8A1F6D2A-A4DC-47E8-B0AF-C0A78B5CE8B3Q38887346-1E1968C8-EB60-4894-AC8C-EE19E101073BQ38905310-C96A4FF9-BE59-4486-9E8B-DD3A02FFBA93Q38978791-9505852A-B381-4C64-A652-BC1F712BC250Q40887263-5F059E84-664F-4C98-990E-D4E9E04572B3Q41203952-10712CAD-89C2-4E4E-BC51-4013C7D16D80Q42148658-5F2717BD-940E-49FE-ABA2-DC727D7490FF
P2860
RTP801 is elevated in Parkinson brain substantia nigral neurons and mediates death in cellular models of Parkinson's disease by a mechanism involving mammalian target of rapamycin inactivation.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@ast
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@en
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@nl
type
label
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@ast
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@en
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@nl
prefLabel
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@ast
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@en
RTP801 is elevated in Parkinso ...... get of rapamycin inactivation.
@nl
P2093
P1476
RTP801 is elevated in Parkinso ...... rget of rapamycin inactivation
@en
P2093
Elizabeth J Ryu
Lloyd A Greene
Subhas C Biswas
Vernice Jackson-Lewis
P304
9996-10005
P356
10.1523/JNEUROSCI.3292-06.2006
P407
P577
2006-09-01T00:00:00Z